Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Operating Expenses (2022 - 2025)

Oramed Pharmaceuticals' Operating Expenses history spans 4 years, with the latest figure at $5.9 million for Q4 2025.

  • For Q4 2025, Operating Expenses changed N/A year-over-year to $5.9 million; the TTM value through Dec 2025 reached $15.3 million, changed N/A, while the annual FY2025 figure was $15.1 million, 18.15% up from the prior year.
  • Operating Expenses reached $5.9 million in Q4 2025 per ORMP's latest filing, up from $2.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $11.8 million in Q4 2022 to a low of $2.4 million in Q3 2025.
  • Average Operating Expenses over 4 years is $5.7 million, with a median of $4.3 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: plummeted 67.04% in 2023, then soared 52.36% in 2025.
  • A 4-year view of Operating Expenses shows it stood at $11.8 million in 2022, then tumbled by 67.04% to $3.9 million in 2023, then fell by 20.32% to $3.1 million in 2024, then skyrocketed by 91.49% to $5.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Operating Expenses are $5.9 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).